Abstract: In certain embodiments, the present disclosure is directed to methods and uses for treating seizure disorders in a human in need thereof, wherein the methods and uses comprise conjointly administering N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A) and an antiseizure medication (ASM) to the human in amounts that are therapeutically effective when conjointly administered. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.

Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.

Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.

Abstract: In certain embodiments, the present disclosure is directed to methods for treating pain in a subject, such as a human, wherein the methods comprise orally administering a therapeutically effective amount of N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), to the subject in need thereof. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.

Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.

Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.

Abstract: This invention is directed to methods of preparing benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.

Abstract: This invention is directed to methods of preparing benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.

Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.

Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.

Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.

Abstract: The invention relates to heterocyclic chromene-spirocyclic piperidine amides useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

Abstract: The invention relates to heterocyclic chromene-spirocyclic piperidine amides useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

Abstract: The invention relates to heterocyclic chromene-spirocyclic piperidine amides useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

Abstract: A switchable color filter (11) includes three polarizing filters (12, 14, and 16) and two zero to substantially half-wave optical retarders (36 and 38) and is incorporated in a field sequential display system (10) to provide output states of light of three different colors to form an image in full color. Each one of four preferred embodiments (11, 11a, 11b, and 11c) of the switchable color filter provides the output states of three colors. The third and fourth preferred embodiments (11b and 11c) provide a fourth additional output state of, respectively, white light and light of a color which is a combination of two of the other output state colors. The optical retarders comprise nematic liquid crystal cells (100) having fast relaxation times to operate the display system at video rates.

Abstract: A switchable color filter (11) includes three polarizing filters (12, 14, and 16) and two zero to substantially half-wave optical retarders (36 and 38) and is incorporated in a field sequential display system (10) to provide output states of light of three different colors to form an image in full color. Each one of four preferred embodiments (11, 11a, 11b, and 11c) of the switchable color filter provides the output states of three colors. The third and fourth preferred embodiments (11b and 11c) provide a fourth additional output state of, respectively, white light and light of a color which is a combination of two of the other output state colors. The optical retarders comprise nematic liquid crystal cells (100) having fast relaxation times to operate the display system at video rates.

Abstract: A field sequential color display system incorporates a color switch which includes a zero to half-wave optical retarder and pleochroic filters to provide an image with high color contrast and resolution over a broad range of display sizes. In a preferred embodiment, a liquid crystal cell which operates between two states of optical retardation comprises the variable retarder to provide a color switch with substantially reduced optical response times.

Abstract: The present invention provides a system for reducing the unproductive consumption of energy by equipment primarily intended to be operated during the presence of a person or thing in the area of operation of the equipment. The system renders the equipment operable during the time a person or thing is present within the area of operation and for a short period of time immediately thereafter. Except for the short period of time immediately after the person or thing exits the area of operation, the system renders the equipment inoperable during the time the person or thing is absent from the area of operation. Maintaining the equipment operable during the short period of time after the person or thing exits the area of operation reduces deleterious recycling which would otherwise occur in the event the area of operation were reentered within the short period of time.